Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of LLF580 in Obese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) within the range of 30 to 45 kg/m2, inclusive, with ethnic adjustment (≥27.5 kg/m2 for Asian individuals).~* Fasting triglyceride 150 - 500 mg/dL (1.69 - 5.65 mmol/L), inclusive, at screening.~* Able to communicate well with the investigator, to understand and comply with the requirements of the study.~Exclusion Criteria:~* History of hepatobilliary disease.~* Liver disease or liver injury as indicated by abnormal liver function tests.~* Chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).~* Fasting triglycerides greater than or equal to 500 mg/dL \[5.65 mmol/L\], or concomitant use of drug treatment for hypertriglyceridemia (fibrates, omega-3 fatty acids, nicotinic acid).~* History of pancreatic injury or pancreatitis.~* History of hypersensitivity to drugs of similar biological class, FGF21 protein analogue, or Fc fusion proteins.~* History of bone disorders or low vitamin D level.~* Contraindications to MRI.~* Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months).~* Use of weight loss drugs.~* Enrollment in a diet, weight loss or exercise programs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LLF580 (Type: EXPERIMENTAL): LLF580 every 28 days \* 3
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to LLF580 every 28 days \* 3

Based on this trial design, predict the completion outcome and termination type (if applicable).